UBIO

ProShares UltraPro Nasdaq Biotechnology
*Unless otherwise stated, data provided by FactSet.

UBIO Fund Description

UBIO provides 3x daily exposure to a market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ.

UBIO Factset Analytics Insight

UBIO offers 3x the daily gains and losses of its index, which is tracked in unlevered form by the hugely popular IBB, from iShares. That means it inherits all of IBB’s quirks—most notably its NASDAQ-only listing requirement, and its inclusion of a good number of pharmaceutical companies outside of the pure-play biotech space. UBIO gains its leverage through a mix of equity and swap agreements, and resets its exposure daily. Like all geared funds that rebalance daily, UBIO is meant for short-term trading, since compounding effects over the long term could create vast differences from expected returns relative to the index—for good or for ill. Note that 2x exposure to the same index can be had from sibling fund BIB. UBIO competes with Direxion’s LABU, which tracks a triple-levered S&P index.

UBIO MSCI ESG Analytics Insight

ProShares UltraPro Nasdaq Biotechnology has an MSCI ESG Fund Rating of BBB based on a score of 4.57 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ProShares UltraPro Nasdaq Biotechnology ranks in the 29th percentile within its peer group and in the 38th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

UBIO Charts And Performance

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
Compare
Reset
Select ETFs to compare their performance:
PERFORMANCE [as of 11/08/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
UBIO 43.26% 9.29% 27.00% -18.28% 6.65% -- --
UBIO (NAV) 43.52% 9.27% 26.92% -17.95% 6.68% -- --
NASDAQ Biotechnology Index 13.27% 4.41% 14.49% 0.80% 8.76% 3.16% --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

UBIO Summary Data

ProShares
06/23/15
Open-Ended Fund
0.95%
$24.02M
0.28%

UBIO Portfolio Data

0.00%
12/24/19

UBIO Index Data

Market Cap
NASDAQ - Listed
N/A

UBIO Fund Structure

Yes
No
No Policy
N/A
N/A
High
3
Daily

UBIO Tax Exposures

20.00% / 39.60%
--
No
Cboe Book Viewer
Top Of Book
Last 10 Trades
Bats BZX Real-time Quote -

UBIO Factset Analytics Block Liquidity

As of 11/11/19
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of UBIO. UBIO is rated a N/A out of 5.

UBIO Tradability

45,379
$963.84K
40,450
$836.63K
0.28%
$0.06
-0.07%
1.29% / -0.91%
None
0.00%
50,000
0.81
0.02%
--
243
$25.46
N/A

UBIO MSCI ESG Ratings

BBB
4.57 / 10
37.63
28.87
0.11%
32.62%
20.53